Abraham, Fruchter & Twersky, LLP Warns
Investors That It is the Only Law Firm That Has
Filed a Class Action Lawsuit Against AMAG
March 25, 2010 04:02 PM Eastern Daylight Time
NEW YORK--(EON: Enhanced Online News)--On March 19, 2010, Abraham, Fruchter & Twersky, LLP filed a
class action lawsuit in the United States District Court for the District of Massachusetts (Case No. 10 Civ. 10470)
on behalf of all investors who purchased or otherwise acquired the common stock of AMAG Pharmaceuticals, Inc.
(NASDAQ: AMAG) (“AMAG” or the “Company”) in the Company’s secondary public offering (“Secondary
Offering”) on or about January 21, 2010.
The complaint, filed by Abraham, Fruchter & Twersky, LLP, is the only securities class action that has been
commenced against the Company to preserve and protect the rights of AMAG investors. Other lawyers, however,
who have not filed complaints of their own, continue to issue press releases, apparently for the sole purpose of
AMAG investors who would like to speak with the attorneys who actually investigated and filed the AMAG
securities class action should contact Abraham, Fruchter & Twersky, LLP, which has extensive experience in the
prosecution of class actions on behalf of investors.
According to the complaint, the defendants made a series of misrepresentations and omissions that actively
concealed and failed to disclose in the Registration Statement that users of the Company’s primary drug, Feraheme,
had suffered adverse reactions, some requiring hospitalization. When the defendants revealed this information on
February 4, 2010, AMAG’s stock plummeted over $7.00 per share.
If you would like to discuss this action or if you have any questions concerning this notice or your rights as a potential
class member or lead plaintiff, you may contact: Jack Fruchter or Arthur J. Chen of Abraham, Fruchter & Twersky,
LLP at 212-279-5050, or via e-mail at firstname.lastname@example.org or email@example.com, respectively.